A Review of Safety and Design Requirements of the Artificial Pancreas

Annals of Biomedical Engineering

Volumn 44, Issue 11, 2016, Pages 3158-3172

  Blauw, Helga ^a,b   Keith Hynes, Patrick ^c,d   Koops, Robin ^b   DeVries, J Hans ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Inreda Diabetic BV   (Netherlands)

^c TypeZero Technologies   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Closed loop system; Diabetes; Medical device development; Risk analysis; Sensors

Indexed keywords

ALGORITHMS; BIOMEDICAL EQUIPMENT; CLOSED LOOP SYSTEMS; DESIGN; ELECTRONIC DATA INTERCHANGE; GLUCOSE; HAZARDS; MEDICAL PROBLEMS; RISK ANALYSIS; RISK ASSESSMENT; SAFETY ENGINEERING; SENSORS; USER INTERFACES;

ARTIFICIAL PANCREAS; CLOSED-LOOP CONTROL; CONTROL MEASURES; HORMONAL SYSTEMS; LITERATURE SEARCH; MEDICAL DEVICE DEVELOPMENT; SAFETY AND DESIGN; SYSTEM CONFIGURATIONS;

ARTIFICIAL ORGANS;

GLUCAGON; GLUCOSE; INSULIN;

ACCURACY; ALARM MONITOR; ALGORITHM; ANALYTICAL EQUIPMENT; ARTIFICIAL PANCREAS; BLOOD GLUCOSE MONITORING; COMPUTER INTERFACE; CONTINUOUS GLUCOSE MONITOR; DEVICE APPROVAL; DEVICE SAFETY; EQUIPMENT DESIGN; GLUCOSE BLOOD LEVEL; GLUCOSE CONTROL ALGORITHM; GLUCOSE SENSOR; HAZARD ASSESSMENT; HUMAN; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT SAFETY; PRIORITY JOURNAL; RELIABILITY; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; WIRELESS COMMUNICATION; ANIMAL; DIABETES MELLITUS, TYPE 1; METABOLISM; SAFETY; SECRETION (PROCESS);

ALGORITHMS; ANIMALS; DIABETES MELLITUS, TYPE 1; GLUCAGON; HUMANS; INSULIN; PANCREAS, ARTIFICIAL; SAFETY;

EID: 84976449580     PISSN: 00906964     EISSN: 15739686     Source Type: Journal    
DOI: 10.1007/s10439-016-1679-2     Document Type: Review

References (79)

1. American Diabetes Association. 6. Glycemic targets. Diabetes Care 38:S33–S40, 2015.
2. Anhalt, H., and N. J. Bohannon. Insulin patch pumps: their development and future in closed-loop systems. Diabetes Technol. Ther. 12(Suppl 1):S51–S58, 2010.
3. Bakhtiani, P. A., J. El Youssef, A. K. Duell, D. L. Branigan, P. G. Jacobs, M. R. Lasarev, J. R. Castle, and W. K. Ward. Factors affecting the success of glucagon delivered during an automated closed-loop system in type 1 diabetes. J. Diabetes Complicat. 29(1):93–98, 2014.
4. Bakhtiani, P. A., L. M. Zhao, J. El Youssef, J. R. Castle, and W. K. Ward. A review of artificial pancreas technologies with an emphasis on bi-hormonal therapy. Diabetes Obes. Metab. 15:1065–1070, 2013.
5. Barnard, K. D., T. Wysocki, H. Thabit, M. L. Evans, S. Amiel, S. Heller, A. Young, R. Hovorka, and C. Angela. Psychosocial aspects of closed- and open-loop insulin delivery: closing the loop in adults with Type 1 diabetes in the home setting. Diabet. Med. 32:601–608, 2015.
6. Beck, R. W., W. V. Tamborlane, R. M. Bergenstal, K. M. Miller, S. N. DuBose, and C. A. Hall. The T1D Exchange clinic registry. J. Clin. Endocrinol. Metab. 97:4383–4389, 2012.
7. Bequette, B. W. Challenges and recent progress in the development of a closed-loop artificial pancreas. Annu. Rev. Control 36:255–266, 2012.
8. Bequette, B. W. Fault detection and safety in closed-loop artificial pancreas systems. J. Diabetes Sci. Technol. 8:1204–1214, 2014.
9. Bergenstal, R. M., D. C. Klonoff, S. K. Garg, B. W. Bode, M. Meredith, R. H. Slover, A. J. Ahmann, J. B. Welsh, S. W. Lee, and F. R. Kaufman. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N. Engl. J. Med. 369(3):224–232, 2013.
10. Blauw, H., A. C. van Bon, R. Koops, J. H. DeVries, and PCDIAB Consortium. Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home. Diabetes Obes. Metab. 18:671–677, 2016.
11. Cameron, F., B. W. Bequette, D. M. Wilson, B. A. Buckingham, H. Lee, and G. Niemeyer. A closed-loop artificial pancreas based on risk management. J. Diabetes Sci. Technol. 5:368–379, 2011.
12. Castle, J. R., J. El Youssef, P. A. Bakhtiani, Y. Cai, J. M. Stobbe, D. Branigan, K. Ramsey, P. Jacobs, R. Reddy, M. Woods, and W. K. Ward. Effect of repeated glucagon doses on hepatic glycogen in Type 1 diabetes: implications for a bihormonal closed-loop system. Diabetes Care 38:2115–2119, 2015.
13. Castle, J. R., J. M. Engle, J. El Youssef, R. G. Massoud, and W. K. Ward. Factors influencing the effectiveness of glucagon for preventing hypoglycemia. J. Diabetes Sci. Technol. 4:1305–1310, 2010.
14. Castle, J. R., A. Pitts, K. Hanavan, R. Muhly, J. El Youssef, C. Hughes-Karvetski, B. Kovatchev, and W. K. Ward. The accuracy benefit of multiple amperometric glucose sensors in people with type 1 diabetes. Diabetes Care 35:706–710, 2012.
15. Castle, J. R., and W. K. Ward. Amperometric glucose sensors: sources of error and potential benefit of redundancy. J. Diabetes Sci. Technol. 4:221–225, 2010.
16. Chassin, L. J., M. E. Wilinska, and R. Hovorka. Evaluation of glucose controllers in virtual environment: methodology and sample application. Artif. Intell. Med. 32:171–181, 2004.
17. Chernavvsky, D. R., M. D. DeBoer, P. Keith-Hynes, B. Mize, M. McElwee, S. Demartini, S. F. Dunsmore, C. Wakeman, B. P. Kovatchev, and M. D. Breton. Use of an artificial pancreas among adolescents for a missed snack bolus and an underestimated meal bolus. Pediatr. Diabetes. 17:28–35, 2016.
18. Clarke, W. L., and E. Renard. Clinical requirements for closed-loop control systems. J. Diabetes Sci Technol. 6:444–452, 2012.
19. Colberg, S. R., R. Laan, E. Dassau, and D. Kerr. Physical activity and type 1 diabetes: time for a rewire? J. Diabetes Sci. Technol. 9(3):609–618, 2015.
20. Damiano, E. R., K. McKeon, F. H. El-Khatib, H. Zheng, D. M. Nathan, and S. J. Russell. A comparative effectiveness analysis of three continuous glucose monitors: the navigator, G4 platinum, and enlite. J. Diabetes Sci. Technol. 8(4):699–708, 2014.
21. Dassau, E., C. C. Palerm, H. Zisser, B. A. Buckingham, L. Jovanovic, and F. J. Doyle. In silico evaluation platform for artificial pancreatic beta-cell development—a dynamic simulator for closed-loop control with hardware-in-the-loop. Diabetes Technol. Ther. 11:187–194, 2009.
22. Davey, R. J., W. Howe, N. Paramalingam, L. D. Ferreira, E. A. Davis, P. A. Fournier, and T. W. Jones. The effect of midday moderate-intensity exercise on postexercise hypoglycemia risk in individuals with type 1 diabetes. J. Clin. Endocrinol. Metab. 98:2908–2914, 2013.
23. Doyle, 3rd, F. J., L. M. Huyett, J. B. Lee, H. C. Zisser, and E. Dassau. Closed-loop artificial pancreas systems: engineering the algorithms. Diabetes Care. 37:1191–1197, 2014.
24. Elleri, D., J. M. Allen, K. Kumareswaran, L. Leelarathna, M. Nodale, K. Caldwell, P. Cheng, C. Kollman, A. Haidar, H. R. Murphy, M. E. Wilinska, C. L. Acerini, D. B. Dunger, and R. Hovorka. Closed-loop basal insulin delivery over 36 hours in adolescents with type 1 diabetes: randomized clinical trial. Diabetes Care 36:838–844, 2013.
25. Elleri, D., M. Biagioni, J. M. Allen, K. Kumareswaran, L. Leelarathna, K. Caldwell, M. Nodale, M. E. Wilinska, A. Haidar, P. Calhoun, C. Kollman, N. C. Jackson, A. M. Umpleby, C. L. Acerini, D. B. Dunger, and R. Hovorka. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial. Diabetes Obes. Metab. 17:1173–1179, 2015.
26. Elleri, D., G. Maltoni, J. M. Allen, M. Nodale, K. Kumareswaran, L. Leelarathna, H. Thabit, K. Caldwell, M. E. Wilinska, P. Calhoun, C. Kollman, D. B. Dunger, and R. Hovorka. Safety of closed-loop therapy during reduction or omission of meal boluses in adolescents with type 1 diabetes: a randomized clinical trial. Diabetes Obes. Metab. 16:1174–1178, 2014.
27. Frier, B. M. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat. Rev. Endocrinol. 10:711–722, 2014.
28. Garcia, A., A. L. Rack-Gomer, N. C. Bhavaraju, H. Hampapuram, A. Kamath, T. Peyser, A. Facchinetti, C. Zecchin, G. Sparacino, and C. Cobelli. Dexcom G4AP: an advanced continuous glucose monitor for the artificial pancreas. J. Diabetes Sci. Technol. 7:1436–1445, 2013.
29. Gondhalekar, R., E. Dassau, H. C. Zisser, and F. J. Doyle, 3rd. Periodic-zone model predictive control for diurnal closed-loop operation of an artificial pancreas. J. Diabetes Sci. Technol. 7:1446–1460, 2013.
30. Haidar, A., D. Farid, A. St-Yves, V. Messier, V. Chen, D. Xing, A. S. Brazeau, C. Duval, B. Boulet, L. Legault, and R. Rabasa-Lhoret. Post-breakfast closed-loop glucose control is improved when accompanied with carbohydrate-matching bolus compared to weight-dependent bolus. Diabetes Metab. 40:211–214, 2014.
31. Heinemann, L., and L. Krinelke. Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion. J. Diabetes Sci. Technol. 6:954–964, 2012.
32. Hernando, M. E., G. Garcia-Saez, I. Martinez-Sarriegui, A. Rodriguez-Herrero, C. Perez-Gandia, M. Rigla, A. de Leiva, I. Capel, B. Pons, and E. J. Gomez. Automatic data processing to achieve a safe telemedical artificial pancreas. J. Diabetes Sci. Technol. 3:1039–1046, 2009.
33. Hinshaw, L., C. Dalla Man, D. K. Nandy, A. Saad, A. E. Bharucha, J. A. Levine, R. A. Rizza, R. Basu, R. E. Carter, C. Cobelli, Y. C. Kudva, and A. Basu. Diurnal pattern of insulin action in type 1 diabetes: implications for a closed-loop system. Diabetes 62:2223–2229, 2013.
34. Hovorka, R. Closed-loop insulin delivery: from bench to clinical practice. Nat. Rev. Endocrinol. 7:385–395, 2011.
35. Hovorka, R., D. Elleri, H. Thabit, J. M. Allen, L. Leelarathna, R. El-Khairi, K. Kumareswaran, K. Caldwell, P. Calhoun, C. Kollman, H. R. Murphy, C. L. Acerini, M. E. Wilinska, M. Nodale, and D. B. Dunger. Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care 37:1204–1211, 2014.
36. Jacobs, P. G., J. El Youssef, J. Castle, P. Bakhtiani, D. Branigan, M. Breen, D. Bauer, N. Preiser, G. Leonard, T. Stonex, and W. K. Ward. Automated control of an adaptive bihormonal, dual-sensor artificial pancreas and evaluation during inpatient studies. IEEE Trans. Biomed. Eng. 61:2569–2581, 2014.
37. Keith-Hynes, P., S. Guerlain, B. Mize, C. Hughes-Karvetski, M. Khan, M. McElwee-Malloy, and B. P. Kovatchev. DiAs user interface: a patient-centric interface for mobile artificial pancreas systems. J. Diabetes Sci. Technol. 7:1416–1426, 2013.
38. Keith-Hynes, P., B. Mize, A. Robert, and J. Place. The diabetes assistant: a smartphone-based system for real-time control of blood glucose. Electronics 3:609–623, 2014.
39. Klonoff, D. C., and D. N. Kleidermacher. Now is the time for a cybersecurity standard for connected diabetes devices. J. Diabetes Sci. Technol. 10:623–626, 2016.
40. Kovatchev, B. P., S. D. Patek, E. A. Ortiz, and M. D. Breton. Assessing sensor accuracy for non-adjunct use of continuous glucose monitoring. Diabetes Technol. Ther. 17:177–186, 2015.
41. Kovatchev, B. P., E. Renard, C. Cobelli, H. C. Zisser, P. Keith-Hynes, S. M. Anderson, S. A. Brown, D. R. Chernavvsky, M. D. Breton, L. B. Mize, A. Farret, J. Place, D. Bruttomesso, S. Del Favero, F. Boscari, S. Galasso, A. Avogaro, L. Magni, F. Di Palma, C. Toffanin, M. Messori, E. Dassau, and F. J. Doyle, 3rd. Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care 37:1789–1796, 2014.
42. Kowalski, A. J. Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technol. Ther. 11(Suppl 1):S113–S119, 2009.
43. Kropff, J., D. Bruttomesso, W. Doll, A. Farret, S. Galasso, Y. M. Luijf, J. K. Mader, J. Place, F. Boscari, T. R. Pieber, E. Renard, and J. H. DeVries. Accuracy of two continuous glucose monitoring systems: a head-to-head comparison under clinical research centre and daily life conditions. Diabetes Obes Metab. 7(4):833–841, 2014.
44. Kropff, J., S. Del Favero, J. Place, C. Toffanin, R. Visentin, M. Monaro, M. Messori, F. Di Palma, G. Lanzola, A. Farret, F. Boscari, S. Galasso, P. Magni, A. Avogaro, P. Keith-Hynes, B. P. Kovatchev, D. Bruttomesso, C. Cobelli, J. H. DeVries, E. Renard, L. Magni, and A. P. h. consortium. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol. 3:939–947, 2015.
45. Kudva, Y. C., R. E. Carter, C. Cobelli, R. Basu, and A. Basu. Closed-loop artificial pancreas systems: physiological input to enhance next-generation devices. Diabetes Care 37:1184–1190, 2014.
46. Leelarathna, L., M. Nodale, J. M. Allen, D. Elleri, K. Kumareswaran, A. Haidar, K. Caldwell, M. E. Wilinska, C. L. Acerini, M. L. Evans, H. R. Murphy, D. B. Dunger, and R. Hovorka. Evaluating the accuracy and large inaccuracy of two continuous glucose monitoring systems. Diabetes Technol. Ther. 15:143–149, 2013.
47. Ly, T. T., M. D. Breton, P. Keith-Hynes, D. De Salvo, P. Clinton, K. Benassi, B. Mize, D. Chernavvsky, J. Place, D. M. Wilson, B. P. Kovatchev, and B. A. Buckingham. Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes camp. Diabetes Care 37:2310–2316, 2014.
48. Ly, T. T., J. A. Nicholas, A. Retterath, E. M. Lim, E. A. Davis, and T. W. Jones. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 310:1240–1247, 2013.
49. Ly, T. T., A. Roy, B. Grosman, J. Shin, A. Campbell, S. Monirabbasi, B. Liang, R. von Eyben, S. Shanmugham, P. Clinton, and B. A. Buckingham. Day and night closed-loop control using the integrated medtronic hybrid closed-loop system in type 1 diabetes at diabetes camp. Diabetes Care 38:1205–1211, 2015.
50. Mauseth, R., I. B. Hirsch, J. Bollyky, R. Kircher, D. Matheson, S. Sanda, and C. Greenbaum. Use of a “fuzzy logic” controller in a closed-loop artificial pancreas. Diabetes Technol. Ther. 15:628–633, 2013.
51. McMahon, S. K., L. D. Ferreira, N. Ratnam, R. J. Davey, L. M. Youngs, E. A. Davis, P. A. Fournier, and T. W. Jones. Glucose requirements to maintain euglycemia after moderate-intensity afternoon exercise in adolescents with type 1 diabetes are increased in a biphasic manner. J. Clin. Endocrinol. Metab. 92:963–968, 2007.
52. Nimri, R., I. Muller, E. Atlas, S. Miller, A. Fogel, N. Bratina, O. Kordonouri, T. Battelino, T. Danne, and M. Phillip. MD-logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care 37:3025–3032, 2014.
53. Nimri, R., and M. Phillip. Artificial pancreas: fuzzy logic and control of glycemia. Curr. Opin. Endocrinol. Diabetes Obes. 21:251–256, 2014.
54. O’Grady, M. J., A. J. Retterath, D. B. Keenan, N. Kurtz, M. Cantwell, G. Spital, M. N. Kremliovsky, A. Roy, E. A. Davis, T. W. Jones, and T. T. Ly. The use of an automated, portable glucose control system for overnight glucose control in adolescents and young adults with type 1 diabetes. Diabetes Care 35:2182–2187, 2012.
55. Oron, T., A. Farfel, I. Muller, S. Miller, E. Atlas, R. Nimri, and M. Phillip. A remote monitoring system for artificial pancreas support is safe, reliable, and user friendly. Diabetes Technol. Ther. 16:699–705, 2014.
56. Patek, S. D., L. Magni, E. Dassau, C. Karvetski, C. Toffanin, G. De Nicolao, S. Del Favero, M. Breton, C. D. Man, E. Renard, H. Zisser, F. J. Doyle, 3rd, C. Cobelli, B. P. Kovatchev, and G. International Artificial Pancreas Study. Modular closed-loop control of diabetes. IEEE Trans. Biomed. Eng. 59:2986–2999, 2012.
57. Paul, N., T. Kohno, and D. C. Klonoff. A review of the security of insulin pump infusion systems. J. Diabetes Sci. Technol. 5:1557–1562, 2011.
58. Peyser, T., E. Dassau, M. Breton, and J. S. Skyler. The artificial pancreas: current status and future prospects in the management of diabetes. Ann. N. Y. Acad. Sci. 1311:102–123, 2014.
59. Picton, P. E., M. Yeung, N. Hamming, L. Desborough, E. Dassau, and J. A. Cafazzo. Advancement of the artificial pancreas through the development of interoperability standards. J. Diabetes Sci. Technol. 7:1066–1070, 2013.
60. Place, J., A. Robert, N. Ben Brahim, P. Keith-Hynes, A. Farret, M. J. Pelletier, B. Buckingham, M. Breton, B. Kovatchev, and E. Renard. DiAs web monitoring: a real-time remote monitoring system designed for artificial pancreas outpatient trials. J. Diabetes Sci Technol. 7:1427–1435, 2013.
61. Reddy, M., P. Herrero, M. El Sharkawy, P. Pesl, N. Jugnee, H. Thomson, D. Pavitt, C. Toumazou, D. Johnston, P. Georgiou, and N. Oliver. Feasibility study of a bio-inspired artificial pancreas in adults with type 1 diabetes. Diabetes Technol. Ther. 16:550–557, 2014.
62. Revert, A., F. Garelli, J. Pico, H. De Battista, P. Rossetti, J. Vehi, and J. Bondia. Safety auxiliary feedback element for the artificial pancreas in type 1 diabetes. IEEE Trans. Biomed. Eng. 60:2113–2122, 2013.
63. Russell, S. J. Progress of artificial pancreas devices towards clinical use: the first outpatient studies. Curr. Opin. Endocrinol. Diabetes Obes. 22:106–111, 2015.
64. Russell, S. J., F. H. El-Khatib, M. Sinha, K. L. Magyar, K. McKeon, L. G. Goergen, C. Balliro, M. A. Hillard, D. M. Nathan, and E. R. Damiano. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N. Engl. J. Med. 371:313–325, 2014.
65. Sanchez, R. M. The critical path from pump to pancreas: the impact of FDA regulation on the development of a closed-loop diabetes management system. Food Drug Law J. 68:53–76, 2013.
66. Schaeffer, N. E. The role of human factors in the design and development of an insulin pump. J. Diabetes Sci. Technol. 6:260–264, 2012.
67. Schiavon, M., C. Dalla Man, Y. C. Kudva, A. Basu, and C. Cobelli. In silico optimization of basal insulin infusion rate during exercise: implication for artificial pancreas. J. Diabetes Sci. Technol. 7:1461–1469, 2013.
68. Stenvers, D. J., J. H. DeVries, and S. E. la Fleur. What’s the Time? Does the Artificial Pancreas Need to Know? Diabetes 62:2173–2174, 2013.
69. Tauschmann, M., and R. Hovorka. Insulin pump therapy in youth with type 1 diabetes: toward closed-loop systems. Expert Opin. Drug Deliv. 11:943–955, 2014.
70. Thabit, H., and R. Hovorka. Bringing closed-loop home: recent advances in closed-loop insulin delivery. Curr. Opin. Endocrinol. Diabetes Obes. 21:95–101, 2014.
71. Thabit, H., M. Tauschmann, J. M. Allen, L. Leelarathna, S. Hartnell, M. E. Wilinska, C. L. Acerini, S. Dellweg, C. Benesch, L. Heinemann, J. K. Mader, M. Holzer, H. Kojzar, J. Exall, J. Yong, J. Pichierri, K. D. Barnard, C. Kollman, P. Cheng, P. C. Hindmarsh, F. M. Campbell, S. Arnolds, T. R. Pieber, M. L. Evans, D. B. Dunger, R. Hovorka, and A. P. Consortium and A. P. h. Consortium. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med. 373:2129–2140, 2015.
72. The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Artificial Pancreas Device Systems. Center for Devices and Radiological Health: U.S. Department of Health and Human Services, Food and Drug Administration, 2012.
73. Turksoy, K., L. T. Quinn, E. Littlejohn, and A. Cinar. An integrated multivariable artificial pancreas control system. J. Diabetes Sci. Technol. 8:498–507, 2014.
74. van Bon, A. C., Y. M. Luijf, R. Koebrugge, R. Koops, J. B. Hoekstra, and J. H. Devries. Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. Diabetes Technol. Ther. 16:131–136, 2014.
75. Visentin, R., C. Dalla Man, Y. C. Kudva, A. Basu, and C. Cobelli. Circadian variability of insulin sensitivity: physiological input for in silico artificial pancreas. Diabetes Technol. Ther. 17:1–7, 2015.
76. Ward, W. K., J. R. Castle, and J. El Youssef. Safe glycemic management during closed-loop treatment of type 1 diabetes: the role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia. J. Diabetes Sci. Technol. 5:1373–1380, 2011.
77. Wilinska, M. E., E. S. Budiman, M. B. Taub, D. Elleri, J. M. Allen, C. L. Acerini, D. B. Dunger, and R. Hovorka. Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies. J. Diabetes Sci. Technol. 3:1109–1120, 2009.
78. Zisser, H. Clinical hurdles and possible solutions in the implementation of closed-loop control in type 1 diabetes mellitus. J. Diabetes Sci. Technol. 5:1283–1286, 2011.
79. Zisser, H., E. Renard, B. Kovatchev, C. Cobelli, A. Avogaro, R. Nimri, L. Magni, B. A. Buckingham, H. P. Chase, F. J. Doyle, 3rd, J. Lum, P. Calhoun, C. Kollman, E. Dassau, A. Farret, J. Place, M. Breton, S. M. Anderson, C. Dalla Man, S. Del Favero, D. Bruttomesso, A. Filippi, R. Scotton, M. Phillip, E. Atlas, I. Muller, S. Miller, C. Toffanin, D. M. Raimondo, G. De Nicolao, R. W. Beck, and G. Control to Range Study. Multicenter closed-loop insulin delivery study points to challenges for keeping blood glucose in a safe range by a control algorithm in adults and adolescents with type 1 diabetes from various sites. Diabetes Technol. Ther. 16:613–622, 2014.